🌍 The Oral GLP-1 Era: From Injection to Independence

💊 Can weight loss achieved with injectable GLP-1 therapies be maintained using an oral agent?   The ATTAIN-MAINTAIN phase 3b trial published in Nature Medicine evaluated once-daily oral orforglipron after prior tirzepatide or semaglutide therapy. Patients maintained substantially more prior weight reduction versus placebo over 52 weeks, while preserving cardiometabolic benefits. 🌍⚖️   A fascinating glimpse into the future of scalable obesity care: oral incretin therapy may improve adherence, accessibility, and long-term maintenance.   #Obesity #GLP1 #Orforglipron #NatureMedicine #Cardiology #Endocrinology #MedicalPodcast #PhysicianEducation